摘要
目的初步探讨利用TG119报告对容积旋转调强放疗(VMAT)计划进行评估的可行性。方法选取6 MV和10 MV能量的X射线,针对TG119报告中的测试病例.在Eclipse治疗系统中依照TG119报告中的要求设计7或9个野的1MRT计划和双弧VMAT计划,采用电离室.MatriXX和Delta 4进行剂量验证,并将结果与TG119报告中多机构测试的结果进行对比.结果IMRT和VMAT计划在系统中的剂量指标均达到了 TG119报告中的要求;在靶区测量点和危及器官测量点,不同能量光子束的VMAT计划的点剂量误差为±2. 55%,1MRT计划的点剂量误差为±1.85%使用6 MV和10 MV能量的X射线时,IMKT计划的平均γ通过率(±3%/3 nim)为99. 38%和99. 53%, VMAT计划的平均γ通过率(士3%/3 mm)为99. 32%和99. 46%,复合射野的γ通过率均在98%以上结论6 MV和10 MV能量光子束的VMAT计划均满足TG119报告验证标准.TG119报告对VMAT技术的剂量学验证基准的确定有一定指导意义.
Objective To preliminarily verify the feasibility of utilizing TG119 report to commission the volumetric modulated arc therapy ( VMAT) plans. Methods Based on the test cases mentioned in TGI 19 report. 7-/9-field intensity-modulated radiation therapy (IMRT) and dual-arc VMAT plans were devised by using two types of beam energy ( 6 MV and 10 MV) in the Eclipse TPS system according to the requirement of this report. All the plans were verified using 0. 125cc semiflex thimble ionization chamber, MatriXX and Delta 4. respectively. The final results were statistically compared with the results measured by multiple institutions in the TG119 report. Results The results of both IMRT and VMAT plans met the requirement of the TG119 report. The discrepancy of point dose in the higli/low dose region of VMAT pIans using different photon beams was ranged from -2. 55% to 2. 55%, and ± 1. 85% for the IMRT plans. The percentage of 7 passing points (±3%/3 mm) for the IMRT plans using 6 MV and 10 MV photon beams was 99. 38% aiul 99. 53%, 99. 32% and 99. 46% for the VMAT plans. The 7 passing rate of the compound field exceeded 98%. Conclusions The VMAT plans with 6 MV and 10 MV photon beams meet the requirement of the TG 119 report. TG119 report provides certain guidance for establishing a benchmark for dosimetry verification of the VMAT plans.
作者
吕梦
张俊
周立新
苏欢繁
曹婷婷
全红
Lyu Merig;Zhang Jun;Zhou Lixin;Su Huanfan;Cao Tingting;Quan Hong(School of Physics and Technology. Wuhan University, Wuhan 430072, China;Department of RadiationOncology, Zhongnan Hospital of Wuhan. University, Wuhan 430071, China;Department of RadiationOncology, Suizhou Central Hospital, Suizhou 441000, China)
出处
《中华放射肿瘤学杂志》
CSCD
北大核心
2019年第3期209-213,共5页
Chinese Journal of Radiation Oncology
基金
国家自然科学基金(10875092、31271511 )
湖北省自然科学基金(2011CDA135,2012FFA130、2012KB04449)
医科达-武汉大学医学物理教学科研基金(250000200).
